Sigma Healthcare Eyes Boots Acquisition

Sigma Healthcare, the owner of the Chemist Warehouse franchise, has confirmed engaging in preliminary discussions concerning a potential acquisition of the prominent British pharmacy chain, Boots. This disclosure addresses recent media speculation about a possible sale.

The pharmaceutical wholesaler and retailer stated that it regularly evaluates opportunities that could enhance shareholder value, while also noting that the progression of any such transaction remains uncertain. The news follows a report by the Financial Times, which identified Sigma Healthcare as one of the potential bidders.

The potential sale process could value the health and beauty retailer, Boots, at approximately $10 billion. Such a move would mark a significant expansion for Sigma into the UK market, building upon its recent acquisition of a controlling stake in Greenlight Healthcare in May. This exploration of a sale also contrasts with earlier considerations for a London initial public offering for Boots.

Boots' owners, having taken control last year through a $10 billion acquisition by private equity firm Sycamore Partners, reportedly entered discussions with potential strategic buyers before Easter. This follows earlier reports from April that indicated Boots' owners were strategizing for a potential London IPO as early as 2027, which also included the possibility of a sale.